What You Should Know:
– Peerbridge Health has announced the launch of its landmark COR-INSIGHT Trial, which will validate the screening and diagnostic capabilities of its Peerbridge Cor® ambulatory ECG wearables.
– The trial seeks to revolutionize cardiovascular and cardiopulmonary monitoring and screening by providing a seamless, non-invasive alternative to traditional diagnostic modalities. The trial will leverage two new proprietary, cutting-edge AI SaMD platforms: CardioMIND, an ECG+ analytical pipeline for cardiovascular indications and sleep disorder; and CardioQSync, a quantum-resonance based approach for extraction of cardiopulmonary and hemodynamic indications from respiratory ECG.
Peerbridge Health: Transforming Cardiac Care with AI-Driven Diagnostics and Monitoring
Peerbridge Health is reshaping cardiac care by introducing Peerbridge Cor®, the first AI-enabled, hospital-grade cardiac diagnostic and monitoring device designed for home use. The Peerbridge Cor platform, based on a patented three-lead AECG wearable that utilizes the Einthoven Triangle, delivers precise, cost-effective cardiac diagnostics. By leveraging continuous ECG data, the platform provides actionable insights that enable early intervention, reduce hospital visits, and ultimately save lives.
Revolutionary Insights from the COR-INSIGHT Trial
The COR-INSIGHT trial is the first to prospectively evaluate multiplexed on-demand diagnostics derived from continuous ECG data in both hospital and home settings. Designed to validate over 30 indications, the trial aims to address critical cardiac conditions, including:
• Ejection Fraction Severity and Heart Failure Diagnostics
• Sleep Apnea Detection
• Advanced Cardiopulmonary Insights such as cardiac output and stroke volume
By eliminating the reliance on imaging, catheter-based techniques, and biochemical assays, COR-INSIGHT represents a paradigm shift in diagnostic precision and accessibility. This wearable, low-burden technology integrates advanced hemodynamic measurements into a single device, revolutionizing how cardiac care is delivered.
Expanding Access to Cardiac Care Across Settings
The Peerbridge Cor wearable is designed to serve patients across the clinical spectrum, from asymptomatic individuals to those awaiting critical interventions like TAVR or ICD placement. Its versatility enables monitoring in outpatient, in-hospital, and home environments, with broad use cases such as:
• Early Disease Detection: With rapid diagnostics for 50% of indications in as little as 5 minutes, the device enables affordable screening in primary care offices, urgent care facilities, and retail clinics.
• Reducing Readmissions: For heart failure patients, 25% of whom are re-admitted within 30 days, at-home hemodynamic monitoring facilitates remote care and early intervention, significantly improving outcomes.
• Enhancing Virtual Cardiology Appointments: Addressing the shortage of cardiologists in rural areas, the wearable provides hospital-grade cardiac function snapshots, enabling virtual cardiology consultations for millions of underserved patients.
Trial Enrollment and Industry Collaboration
The COR-INSIGHT trial will enroll up to 15,000 participants from diverse demographics, ensuring robust, real-world data to inform its findings. Peerbridge is partnering with the HeartX program and leading institutions such as HCA, Mercy Health, and Louisiana Cardiology Associates to expand enrollment in early 2025.
With over 160 million adult Americans at risk for conditions being validated in the trial, the Peerbridge Cor platform holds immense potential to transform cardiac care by making diagnostics more accessible, affordable, and actionable.
